NCT05678205View on ClinicalTrials.gov

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 1, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

AB-201

NK Cell Therapy

DRUG

Cyclophosphamide

Lymphodepleting chemotherapy

DRUG

Fludarabine

Lymphodepleting chemotherapy

Trial Locations (2)

16247

The Catholic University of Korea, St. Vincent's Hospital, Suwon

97239

Oregon Health Science University (OHSU), Portland

Sponsors
All Listed Sponsors
lead

Artiva Biotherapeutics, Inc.

INDUSTRY

NCT05678205 - A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | Biotech Hunter | Biotech Hunter